The Indian government has rejected a request by local company Lee Pharma to issue a compulsory licence for AstraZeneca’s diabetes drug Onglyza (saxagliptin).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, compulsory licence, Indian Patent Office, patent, Onglyza, Lee Pharma, saxagliptin